China Sildenafil and Pregabalin Market Investigation Reports Forecast to 2018 Now Available at ChinaMarketResearchReports.com
Dallas, TX (PRWEB) March 11, 2014 -- There are hundreds of millions of males suffering from sexual dysfunction in the world, of which over 50 million are in China. Statistics indicates that more than 60% of males aged above 35 in China have sexual dysfunction of different degrees. About 50% of the causes of erectile dysfunction are organic, and 30% are psychological while 20% of them are organic and psychological at the same time. Erectile dysfunction can have severe psychological consequences as it can be tied to relationship difficulties and masculine selfimage generally. Consequently many pharmaceutical enterprises are very concerned about male sexual dysfunction drug market.
Sildenafil, developed by Pfizer Co., Ltd., was originally developed as a phosphodiesterase type 5 inhibitor (PDE5 inhibitor) to treat cardiovascular diseases. However, the medicine did not avail against the disease. In April 1991, the clinical research of sildenafil officially failed, but a side effect in the report attracted the researchers' attention. They found that patients were unwilling to return the remaining medication after the trial. Through further investigation researchers discovered that the medication can improve the patients' sexual life. Under the permission of Pfizer's top management, experiment about sildenafil's effect on penile corpus cavernosum smooth muscle was carried out. The medication (sildenafil produced by Pfizer with the trade name "Viagra") was approved to the market by FDA on March 27, 1998, which soon became a worldfamous product of Pfizer Co., Ltd.
Besides erectile dysfunction, sildenafil is also useful for the prevention and treatment of highaltitude pulmonary edema and altitude sickness.
Complete report on Sildenafil Market available @ http://www.chinamarketresearchreports.com/114743.html . Or Purchase this report @ http://www.chinamarketresearchreports.com/contacts/purchase.php?name=114743 .
Neuropathic pain is caused by damage or pathological changes of nervous system. Its main features are dull pain, aestus and tingling. About 1% of people worldwide have neuropathic pain. Epileptic seizures are the result of excessive and abnormal cortical nerve cell activity in the brain. It is a group of longterm neurological disorders. As a chronic disease, epilepsy can seriously damage patients' mental and physical health and become a huge burden for their families and the society. According to WHO, the global number of epilepsy patients is higher than 50 million and over 9 million of them are in China.
Pfizer Co., Ltd. submitted registration application for Pregabalin (produced by Pfizer with the trade name "Lyrica") in the U.S. in 2003. In December 2004 pregabalin was approved by FDA to treat diabetic neuropathic pain and postherpetic neuralgia. It is the first drug approved to treat both the two diseases in the U.S.A. and in Europe. In June 2005, pregabalin was approved to be used in the adjuvant treatment of adults with partialonset seizures in epilepsy. After that, it was approved to treat generalized anxiety disorder and fibromyalgia syndrome successively. Time Magazine named pregabalin as one of the "Top 10 Medical Progress" in 2007. Total revenue of pregabalin is more than USD 20 billion. The global sales revenue of Lyrica was approximately USD 4.16 billion, increased by 13% YOY.
In 2010 Lyrica was approved to China. According to CRI's market investigation, the sales revenue of Lyrica in Chinese sample hospital market grew over 100 times from 2010 to 2013. Due to Lyrica's success, many pharmaceutical manufacturers in China begin to apply for pregabalin production. Chongqing Succeway Pharmaceutical Co., Ltd. received production license in 2013. Lyrica produced by Pfizer is expected to be the main product in Chinese market in recent years. However, its market share will decline in 2014 due to competition from relatively cheap homemade drugs.
Complete report on Pregabalin Market available @ http://www.chinamarketresearchreports.com/114740.html . Or Purchase this report @ http://www.chinamarketresearchreports.com/contacts/purchase.php?name=114740 .
Browse more reports on Life Sciences Industry @ http://www.chinamarketresearchreports.com/cat/life-sciences.html .
About Us:
ChinaMarketResearchReports.com (http://www.chinamarketresearchreports.com/ .) is an online database of market research reports offers in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Priyank, Chinamarketresearchreports.com, http://www.chinamarketresearchreports.com/, +1 (888) 391-5441, [email protected]
Share this article